Semaglutide: From GLP-1 Biology to Ozempic and Wegovy

Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. It is approved by the FDA under three brand names: Ozempic (subcutaneous injection for type 2 diabetes, 2017), Wegovy (subcutaneous injection for chronic weight management, 2021), and Rybelsus (oral tablet for type 2 diabetes, 2019). Each formulation uses the same active molecule delivered differently.

Semaglutide occupies a distinctive position in the GLP-1 class because it is the first GLP-1 receptor agonist to demonstrate cardiovascular benefit in people without diabetes (SELECT trial, 2023) — extending its clinical relevance beyond glycemic control.

Structural Design: How Semaglutide Achieves Weekly Dosing

Native GLP-1 has a plasma half-life of approximately 1–2 minutes due to rapid cleavage by DPP-4. Semaglutide overcomes this through three structural modifications applied to the native GLP-1(7-37) backbone:

1. Aib substitution at position 8: Replacing alanine at position 8 with alpha-aminoisobutyric acid (Aib) blocks DPP-4 cleavage at the critical N-terminal site. This modification alone extends half-life substantially.

2. Lys34→Arg substitution: A single amino acid substitution that provides a site for attaching the albumin-binding linker without disrupting receptor binding.

3. C18 fatty diacid chain at Lys26: Via a hydrophilic linker, a C18 fatty diacid is attached that enables reversible, high-affinity binding to serum albumin. Albumin has a plasma half-life of approximately 19 days; the resulting semaglutide-albumin complex achieves a terminal half-life of approximately 7 days in humans — making once-weekly subcutaneous dosing practical.

This is the same albumin-binding strategy used in CJC-1295 (via the Drug Affinity Complex technology), applied here with greater precision and optimization for a specific therapeutic target.

Oral Semaglutide (Rybelsus): Breaking the Oral Peptide Barrier

The development of an orally bioavailable form of semaglutide — Rybelsus — represents a significant achievement in pharmaceutical peptide delivery. The oral formulation co-administers semaglutide with SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), an absorption enhancer that transiently increases gastric pH, reduces proteolytic activity locally, and facilitates transcellular absorption through the gastric mucosa.

The oral bioavailability of semaglutide via this route is approximately 1% — low in absolute terms but sufficient to achieve therapeutic plasma concentrations with a 14mg daily dose. This compares favorably to the essentially zero bioavailability of most unmodified peptides taken orally.

The PIONEER trial program established the efficacy and safety of oral semaglutide across multiple doses and patient populations. For a discussion of why oral peptide delivery is generally challenging, see Peptide Bioavailability: Routes of Administration.

Key Clinical Trials

STEP Program (Weight Management)

The STEP (Semaglutide Treatment Effect in People with Obesity) trial program evaluated weekly subcutaneous semaglutide 2.4mg (Wegovy dose) specifically for weight management in people with obesity or overweight.

STEP 1 enrolled 1,961 adults with BMI ≥30 (or ≥27 with at least one weight-related comorbidity) without diabetes. At 68 weeks, participants receiving semaglutide 2.4mg achieved a mean weight reduction of 14.9% from baseline, compared to 2.4% with placebo.[] This effect size — approximately 15.3kg of weight loss — was substantially larger than previously approved weight loss medications.

STEP 2 examined people with type 2 diabetes and obesity; the weight loss was approximately 9.6%, reflecting the known attenuation of GLP-1 agonist weight effects in people with diabetes.[]

STEP 3 and STEP 4 explored behavioral interventions and maintenance of weight loss after cessation. STEP 4 demonstrated that discontinuing semaglutide after 20 weeks led to significant regain of weight by week 68, establishing that continued treatment is necessary to maintain effect.

SUSTAIN-6 (Cardiovascular Outcomes in T2D)

The SUSTAIN-6 trial enrolled 3,297 people with type 2 diabetes at high cardiovascular risk and compared weekly semaglutide 0.5mg and 1mg (Ozempic doses) versus placebo over approximately 2 years.[]

The primary composite outcome — major adverse cardiovascular events (MACE: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) — occurred in 6.6% of semaglutide-treated patients versus 8.9% in the placebo group. This 26% relative risk reduction was primarily driven by a reduction in nonfatal stroke.

SUSTAIN-6 was a cardiovascular safety trial, not powered specifically for efficacy; the findings led to further investigation, including SELECT.

SELECT (CV Outcomes in Non-Diabetics)

The SELECT trial is the most significant expansion of semaglutide's clinical evidence base. It enrolled 17,604 adults with overweight or obesity and pre-existing cardiovascular disease but without diabetes.[]

At a median follow-up of 39.8 months, semaglutide 2.4mg reduced the risk of the MACE composite endpoint by 20% versus placebo (6.5% vs 8.0% of participants). This was the first time a weight-loss medication had demonstrated a reduction in cardiovascular events in a primary prevention-type population.

SELECT's findings supported an FDA label update in 2024 for Wegovy to include reduction of serious cardiovascular events as an approved indication.[]

Approved Indications (as of writing)

Brand Name	Route	Approved Dose	Primary Indication
Ozempic	SC weekly	0.5mg, 1mg, 2mg	Type 2 diabetes mellitus
Wegovy	SC weekly	2.4mg	Chronic weight management; CV risk reduction
Rybelsus	Oral daily	7mg, 14mg	Type 2 diabetes mellitus

Safety Profile

Common adverse effects reported across trials:

• Gastrointestinal: nausea (very common, especially during dose escalation), vomiting, diarrhea, constipation
• Injection site reactions (SC formulations)
• Mild increases in heart rate

Black box warning: All semaglutide products carry a warning about thyroid C-cell tumors observed in rodent studies at clinically relevant exposures. The human relevance is unknown; semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Pancreatitis: Cases of acute pancreatitis have been reported. The causal relationship is debated in the literature.

Weight regain after discontinuation: As noted in STEP 4, the weight loss from semaglutide is not maintained after stopping treatment. This has important implications for how the treatment is understood — it is a chronic medication, not a curative one.

Positioning Relative to Other GLP-1 Class Drugs

Semaglutide is often compared to tirzepatide (a dual GIP/GLP-1 agonist) and retatrutide (a GIP/GLP-1/glucagon triple agonist currently in Phase III trials). Head-to-head trial data between semaglutide and tirzepatide is limited; the SURMOUNT-5 trial is investigating this comparison directly. For the broader context of how incretin pharmacology evolved to produce these compounds, see GLP-1 Receptor Agonists: From Peptide Biology to Clinical Research.